Anders Wittrupaffiliated with the university
Despite recent advances, there is still a substantial unmet medical need for novel cancer therapeutics. A new class of pharmacological compounds, based on RNA, open up new possibilities to specifically target numerous cancer cell vulnerabilities. Cytosolic delivery of the macromolecular RNA molecules is the biggest hurdle to translate these molecules into clinically useful drugs. Still, a few RNA based drugs have entered clinical use and delivery to certain human tissues, notably the liver and CNS, is possible. However, to reach other tissues, and in particular tumors, the delivery process has to be improved significantly.
In our lab we have two main focus areas: First, we develop methods to study the process of cytosolic delivery of RNA. In particular, we have developed high resolution microscopy methods to study RNA delivery in living cells. Second, based on the insights from these studies we are developing novel strategies to enhance RNA delivery to tumors. These efforts have the potential to specifically turn off driving cancer genes and ultimately halt disease progression.
Recent research outputs
Research output: Contribution to journal › Review article
Research output: Contribution to journal › Article